What is liquid biopsy and how is it different from a tissue biopsy

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Liquid Biopsy vs. Tissue Biopsy: Understanding the Difference

What is a Liquid Biopsy?

A liquid biopsy is a blood test that detects cancer-related material circulating in your bloodstream. Instead of removing tissue from a tumor, doctors analyze blood samples to look for:

  • Circulating tumor DNA (ctDNA) — fragments of DNA shed by cancer cells
  • Circulating tumor cells (CTCs) — actual cancer cells floating in the blood
  • Exosomes — tiny particles released by cancer cells containing genetic material
  • Tumor markers — proteins produced by cancer cells

Think of it as "catching" cancer signals in your blood rather than going directly to the source.

How Tissue Biopsy Works (For Comparison)

A tissue biopsy involves physically removing a small sample of tumor tissue (usually with a needle or during surgery) and examining it under a microscope. This is the traditional, gold-standard approach for cancer diagnosis.

Key Differences

| Aspect | Liquid Biopsy | Tissue Biopsy | |--------|---------------|---------------| | How it's done | Blood draw | Needle insertion or surgery | | Invasiveness | Minimally invasive | More invasive | | Timing | Quick results possible | Takes longer | | What it detects | Cancer DNA/cells in blood | Actual tumor tissue structure | | Current use | Monitoring, early detection research | Diagnosis, detailed analysis |

Current Clinical Applications

According to NCCN Guidelines and ASCO recommendations, liquid biopsies are increasingly used for:

  • Monitoring treatment response — tracking whether cancer DNA levels decrease during therapy
  • Detecting recurrence early — identifying cancer returning before imaging shows it
  • Identifying mutations — finding specific genetic changes that guide treatment selection
  • Minimal residual disease (MRD) detection — checking if cancer remains after treatment

However, liquid biopsies typically complement rather than replace tissue biopsies for initial diagnosis, since tissue analysis provides crucial information about tumor structure and specific characteristics.

Important Limitations

Liquid biopsies are still evolving. The American Cancer Society notes that while promising, they're not yet standard for all cancer types and situations. A negative liquid biopsy doesn't definitively rule out cancer, and positive results need clinical correlation.

Questions to Ask Your Doctor

If your care team mentions liquid biopsy:

  1. "Is a liquid biopsy appropriate for monitoring my specific cancer?"
  2. "Will this replace my tissue biopsy or complement it?"
  3. "How often would I need liquid biopsies, and what would the results tell us?"
  4. "Are there specific mutations or markers you're looking for in my blood?"

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter